Our Executive Team

Designated CEO:

Grégory LAMBERT

 

Pharm.D., Ph.D.

Gregory LAMBERT carrier is split between biotech and pharma where he occupied the jobs of VP R&D and CSO in companies such as Novagali Pharma (now Santen) and Septodont. His responsibilities covered innovation,  CMC, pre-clinical and Clinical development in Europe and north America. He was also in charge of the IP, involved in the Business development and general manager.  Gregory is inventor on more than 20 patents, he was involved in the IPO of Novagali Pharma and he drove the development several pharmaceutical products from the laboratory to market authorizations. In 2014, Gregory joined the scientific founders of TargEDys as CEO to setup the business plan and start operations.

Medical referent:

Pierre DECHELOTTE

 

MD, Ph.D.

MD 1990, Gastroenterologist, Rouen – PhD 1992, Paris - Post-doctorant  1993, Hannover.

Professor of human Nutrition and Head of Clinical Nutrition, Rouen University Hospital

Past-President of European Society for Clinical Nutrition & Metabolism (ESPEN 2010)

Original papers : 120 ; h-index 26. Inventor of 8 patents. BWA now TargEDys co-founder.

Scientific referent:

Serguei FETISSOV

 

MD, Ph.D.

MD 1989, Medical-Military Academy, St.Petersburg - PhD 1995, Inst. Dev. Biology, Russian Acad Sci., Moscow.

College de France-2 yrs, NY Upstate Medical Univ, USA-3 yrs, Karolinska Inst, Stockhlom, Sweden-4 yrs.

Professor physiol. Rouen Univ. from 2004.

Original papers: 85, h-factor: 25, General Nutrition Award, Nestlé Nutrition Inst USA, 2008, Editorial board member Nutrition, BWA, now TargEDys co-founder and main inventor of 5 patents.

Our Board of Directors

Our board of directors is composed of Pierre Déchelotte, Président, Grégory Lambert, CEO, as well as of the following members :

Isabelle de Crémoux

 

President & CEO

Seventure Partners

 

Isabelle is President and CEO of Seventure Partners and manages the Life Sciences team. Seventure Partners is a Paris-based venture capital organization focused on innovation in life sciences and ICT. The broad focus areas within life sciences are therapeutics, medical devices and diagnostics and nutrition. The specific "core" of Seventure's investment strategy is "health, biotech, nutrition and wellness", with particular focus on the microbiome.Isabelle brings 25 years of international experience in life sciences business development and finance. Formerly, Isabelle started her career in '91 at Arthur Andersen Detroit, US then at Pfizer France and Pfizer Europe where she held several positions during 6 years in the field of management accounting, clinical research then Business Development. Since '98, she was Associate Director of Business Development at Fournier/Abbott and signed several deals in Europe and in the US. Isabelle graduated as an engineer from Ecole Centrale of Paris and holds DECF and ISEB degrees and joined Seventure in July 2001 to create the life sciences department.

Isabelle leads the life sciences team and makes direct investments, mainly in France and Scandinavia and in the US/Canada  with a focus on biotech, nutrition, personalized medicine and especially microbiome.Isabelle’s trackrecord includes Santaris (sold to Roche for $450 millions in august 2014), Argenx (listed), OPI pharma (sold to Eusa for Euro 110 millions), Bioalliance (listed), Pixium Vision (listed), as well as Enterome Bioscience, Maat Pharma and Targedys.

Eric de la Fortelle

 

Venture Partner

Seventure Partners

 

Eric is a Venture Partner with Seventure Partners, a Paris-based VC investor investing broadly in life sciences (Rx, Dx, medical device) with a specific focus on the human microbiome. Seventure has raised the first fund worldwide dedicated to the microbiome, called Health for Life, in Dec 2015. Eric sits on the Board of directors of Mint Solutions, Maat Pharma and TargEDys as a representative for Seventure, and of Sensorion (France) as an independent director. Formerly, Eric was CEO of Delenex Therapeutics, a Zurich-based biotechnology company discovering and developing antibodies for topical application to the skin. Prior to that he led Roche’s global function of External Research and Technologies. In this role, he had a dual mandate of BD&L (finding partners, negotiating contracts, managing alliances), leading to more than 200 deals being signed, and prospective (future scenarios to 2020 and R&D strategy recommendations). Eric is a scientist by training, with contributions in the field of protein structure determination by X-ray crystallography. He was trained as an engineer and physicist at Ecole Centrale de Paris, holds a Ph.D. in Biophysics from Paris XI University, a post-graduate diploma in biomedicine from IFSBM (Institut Gustave-Roussy), and an MBA (honors) from INSEAD.

Danilo Casadei-Massari

 

Independant Board Member

 

Danilo has extensive experience as a senior pharmaceutical executive and as a highly successful serial entrepreneur. Most recently he was a founder and President of CM&D Pharma Ltd, a medical foods company he founded in 2007 and sold to Nestle Health Science in 2011. He is currently a Director on the boards of companies based in the USA, Italy, Ireland, Finland and France as well as a Cofounder in some of them. Danilo is an expert in start-ups and co-ventures in the pharmaceutical sector.

Laurie Périé

 

Investment analyst

NCI

 

Laurie is an investment analyst at NCI, a Normandy-based structure which invests in companies operating in Normandy and in Paris. NCI accompanied more than 130 firms at different stages (VC, LBO, growth capital…) and in diverse industries. With a double-digit growth track record, and €180M in managed assets (entrusted by public and private institutional investors), NCI conciliates finance and economic development.

Laurie graduated from Rouen Business School in Corporate Finance and passed all the three levels of the CFA Program.

Ohad  Hammer

 

Analyst

Pontifax

 

Ohad is an analyst at Pontifax, a healthcare-dedicated VC based in Israel. He joined Pontifax in 2009 and focuses on early stage biotechnology investments with an emphasis on oncology and rare diseases. Ohad's work primarily revolves around evaluating new investment opportunities and company creation. He holds a M.S. in biology from Tel-Aviv University.

Tweets de TargEDys @TargEDys